Table 1.
Melanoma-associated circRNAs in the included articles.
| Melanoma type | Circular RNA | Expression level | Target miRNA or proteins | Downstream proteins and signaling pathways | Function/clinical association | Model | Sample/cell line | Methodological quality | Location | References |
|---|---|---|---|---|---|---|---|---|---|---|
| Uveal melanoma | circ_0119873 circ_0128533 circ_0047924 circ_0103232 circRNA10628-6 |
Up | ND | ND | ND | Human | 20 melanomas vs. 20 normal tissues | Good | China | Yang et al., 2018 |
| circ_0032148 circ_0133460 |
Down | ND | ND | ND | ||||||
| Metastatic melanoma | circ_0000082 circ_0016418 |
Up | ND | ND | Promotes cell proliferation, migration and invasio | In vitro | WM35 and WM451 | NA | China | Wang M. et al., 2018 |
| circ_0023988 circ_0008157 circ_0030388 |
Down | ND | ND | Inhibits cell proliferation, migration and invasion | ||||||
| Metastatic oral mucosal melanoma | circ_0005320 circ_0067531 circ_0008042 | Up | ND | GTPase†
MAPK pathway† Translation repressor† |
Correlates with metastasis† | Human | 30 melanomas vs. 30 normal tissues | Good | China | Ju et al., 2018 |
| circ_0000869 circ_0000853 |
Down | ND | G-protein coupled receptor pathway†
NF-kappa B pathway† |
Correlates with metastasis† | ||||||
| Melanoma | circ_0084043 | Up | miR-153-3p | Snail | Promotes cell proliferation, migration and invasion; correlates with TNM stage and overall survival | In vitro, in vivo, human | A375, SK-MEL-1, SK-MEL-5 and A875; mice; 33 melanomas vs. 33 normal tissues |
Good | China | Luan et al., 2018 |
| Melanoma | circ_0025039 | Up | miR-198 | CDK4 | Promotes cell proliferation, invasion and glycolysis; correlates with TNM stage and overall survival | In vitro, human | A375, SK-MEL-1, A2058 and 293T; 43 melanomas vs. 18 paired normal tissues |
Good | China | Bian et al., 2018 |
| Conjunctival melanoma | circ_0083444 (circ-MTUS1) |
Up | miR-622, miR-1208† | ErbB pathway, MAPK pathway, and Wnt pathway† | Promotes cell proliferation | In vitro, in vivo, human | CRMM-1, CRMM-2 and CM2005.1; NOD/SCID mice; not mentioned | Good | China | Shang et al., 2019 |
| Melanoma | circ-ITCH | Down | ND | GLUT1 | Promotes cell proliferation and glucose uptake | In vitro, human | A375 and M21; 56 melanomas vs. 56 normal tissues | Good | China | Lin et al., 2019 |
| Cutaneous melanoma | circ_0016418 | Up | miR-625 | YY1 | Promotes cell proliferation, migration, invasion and epithelial to mesenchymal transition |
In vitro, human | SKMEL1 and SKMEL5; 30 melanomas vs. 30 normal tissues | Good | China | Zou et al., 2019 |
| Melanoma | circ_0020710 (circ-CD151) | Up | miR-370-3p | CXCL12 | Promotes cell proliferation, migration and invasion; correlated with advanced Breslow depth, Clark level, cytotoxic lymphocyte exhaustion and anti-PD-1 therapy resistance | In vitro, in vivo, human | A375, A2058, A875, Sk-mel-28, MV3, M14; C57BL/6 mice; 88 melanomas vs. 88 normal tissues and 18 benign nevi tissues | Good | China | Wei et al., 2020 |
| Melanoma | circ_0002770 | Up | miR-331-3p | DUSP5/TGFBR1 axis | Promotes cell proliferation, invasion and migration; correlated with a poor prognosis | In vitro, in vivo, human | SKMel1,A375 and A875; nude mice; 20 melanomas vs. 20 normal tissues | Good | China | Qian et al., 2020 |
| Melanoma | circ-FOXM1 | Up | miR-143-3p | FLOT2 | Promotes cell proliferation, invasion and glycolysis; inhibits apoptosis | In vitro, in vivo, human | A2058 and A375; BALB/c nude mice; 30 melanomas vs. 30 normal tissues | Good | China | Tian et al., 2020 |
| Primary cutaneous melanoma | circ_0084043 | Up | miR-429 | TRIB2; Wnt/β- catenin pathway |
Promotes cell proliferation, migration and invasion; inhibits apoptosis | In vitro, in vivo, human | A375 and SK-MEL-28, BALB/C-nude mice; 30 melanomas vs. 30 normal tissues | Good | China | Chen J. et al., 2020 |
| Melanoma | circ_0085533 (circ-MYC) | Up | miR-1236 | LDHA | Promotes cell proliferation, glycolysis, and lactate production | In vitro, human | Mel-CV and Mel-RM; 25 melanomas vs. 25 normal tissues | Good | China | Jin et al., 2020 |
| Cutaneous melanoma | ciRS-7 (CDR1as) | Down | IGF2BP3 | SNAI2, MEF2C, etc. | Promotes cell invasion and metastasis; correlates with progression-free, overall survival and distinct therapeutic responses | In vitro, in vivo, human | 501MEL and etc.; mice; 105 (53 primary melanomas vs. 52 metastatic melanomas) | Good | The United States | Hanniford et al., 2020 |
| Melanoma | circ_0027247 (circ-GLI1) | Up | RPS6KB2 (p70S6K2) | Hedgehog/GLI1 pathway and Wnt/β-catenin pathway | Promotes cell migration, invasion, angiogenesis and metastasis | In vitro, in vivo | A375, MEL-RM, B16, M14, SK-MEL-2, SK-MEL-28; BALB/c nude mice | NA | China | Chen J. et al., 2020 |
| Melanoma | circ_0016418 | Up | miR-605-5p | GLS | Promotes cell proliferation, metastasis, glutamine catabolism and tumor growth; inhibits cell cycle arrest and apoptosis | In vitro, in vivo, human | HEMn-LP, A375 and A875; BALB/c nude mice; 30 melanoma vs. 30 normal tissues | Good | China | Lu et al., 2020 |
| Cutaneous melanoma | circ_0079593 | Up | miR-516b | GRM3 | Promotes cell proliferation, metastasis, glucose metabolism; inhibits apoptosis | PIG1, A357 and SK-MEL-2; BALB / c-nude mice; 41 melanomas vs. 41 normal tissues | Good | China | Lu et al., 2020 | |
| Melanoma | circ_0001591 | Up | miR-431-5p | ROCK1/PI3K/AKT | Promotes cell proliferation and invasion; inhibits apoptosis; correlates with overall survival and disease-free survival | In vitro, human | A2058; 53 blood serums of patients with melanoma vs. 53 blood serums of healthy controls | Good | China | Yin et al., 2021 |
| Uveal melanoma | circ_0119872 | Up | miR-622 | G3BP1; Wnt/β-catenin pathway and mTOR pathway | Promotes cell proliferation, angiogenesis and tumor growth | In vitro, in vivo, human | APRE-19, SP6.5, VUP, OCM-1, 92–1, OCM-1A, MUM-2B, and OM431; BALB/c-nude mice; not mentioned | Good | China | Liu et al., 2021 |
†
Only predicted by bioinformatics analysis.
ND, not determined; NA, not applicable.